• TriSalus Life Sciences highlighted publication of a real-world study of its Pressure-Enabled Drug Delivery technology in liver-directed cancer procedures, posted online April 9, 2026 in Journal of Comparative Effectiveness Research; results were already presented in the paper.
• Analysis of patients treated between January 2020 and March 2024 found improved post-procedure outcomes for PEDD use despite higher baseline illness severity versus non-PEDD care.
• Study also pointed to fewer complications, better tolerance for subsequent therapy, and lower healthcare utilization, supporting a value proposition for broader adoption in interventional oncology.
• Economic findings showed mean per-patient charge avoidance of USD 7,734, driven by reduced inpatient stays and fewer clinical complications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512758462) on May 12, 2026, and is solely responsible for the information contained therein.